JP2014208601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014208601A5 JP2014208601A5 JP2013221231A JP2013221231A JP2014208601A5 JP 2014208601 A5 JP2014208601 A5 JP 2014208601A5 JP 2013221231 A JP2013221231 A JP 2013221231A JP 2013221231 A JP2013221231 A JP 2013221231A JP 2014208601 A5 JP2014208601 A5 JP 2014208601A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- marker substance
- mast cells
- prematurity
- retinopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims 10
- 239000003550 marker Substances 0.000 claims 8
- 210000003630 histaminocyte Anatomy 0.000 claims 7
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940122598 Tryptase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011419 induction treatment Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000013513 substance screening Methods 0.000 claims 1
- 239000013076 target substance Substances 0.000 claims 1
- 239000002750 tryptase inhibitor Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013221231A JP6284341B2 (ja) | 2012-10-24 | 2013-10-24 | 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012234729 | 2012-10-24 | ||
| JP2012234729 | 2012-10-24 | ||
| JP2013066295 | 2013-03-27 | ||
| JP2013066295 | 2013-03-27 | ||
| JP2013221231A JP6284341B2 (ja) | 2012-10-24 | 2013-10-24 | 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014208601A JP2014208601A (ja) | 2014-11-06 |
| JP2014208601A5 true JP2014208601A5 (https=) | 2016-12-08 |
| JP6284341B2 JP6284341B2 (ja) | 2018-02-28 |
Family
ID=50544746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013221231A Active JP6284341B2 (ja) | 2012-10-24 | 2013-10-24 | 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10330670B2 (https=) |
| EP (1) | EP2913062B1 (https=) |
| JP (1) | JP6284341B2 (https=) |
| CA (1) | CA2888899C (https=) |
| WO (1) | WO2014065374A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191548A1 (es) | 2017-02-10 | 2019-10-24 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
| JP7477761B2 (ja) | 2020-06-09 | 2024-05-02 | 富士通オプティカルコンポーネンツ株式会社 | モード変換素子 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| EP1884236B1 (en) | 2005-05-17 | 2011-03-02 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor containing amine derivative as active ingredient |
| JP2006348023A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミン誘導体を有効成分として含む血管新生阻害剤 |
| US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| EP2148695B1 (en) | 2007-04-18 | 2014-10-15 | Premacure AB | Method and product for treatment and/or prevention of complications of prematurity |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| KR101116868B1 (ko) | 2008-10-20 | 2012-02-29 | 성균관대학교산학협력단 | 안질환의 예방 또는 치료용 조성물 |
| JP5791064B2 (ja) | 2009-07-17 | 2015-10-07 | エア・ウォーター株式会社 | 医薬用組成物 |
| PL2470191T3 (pl) * | 2009-08-24 | 2014-09-30 | Stealth Peptides Int Inc | Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych |
| US8586044B2 (en) * | 2010-05-28 | 2013-11-19 | Northwestern University | Treatment of chronic pelvic pain syndrome |
-
2013
- 2013-10-24 JP JP2013221231A patent/JP6284341B2/ja active Active
- 2013-10-24 CA CA2888899A patent/CA2888899C/en active Active
- 2013-10-24 US US14/437,925 patent/US10330670B2/en active Active
- 2013-10-24 EP EP13848627.9A patent/EP2913062B1/en active Active
- 2013-10-24 WO PCT/JP2013/078849 patent/WO2014065374A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| WO2015066611A3 (en) | Microrna profiles in heart failure: methods and systems for detection and use | |
| BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| WO2016073380A8 (en) | Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment | |
| WO2014179424A3 (en) | Lipidomic biomarkers | |
| MX2014006904A (es) | Método y sistema para determinar la regularidad asociada a los trastornos del ritmo biológico. | |
| JP2015523410A5 (https=) | ||
| BR112015003046A2 (pt) | sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador. | |
| MX2017002134A (es) | Agente para el tratamiento y/o prevencion de enfermedades asociadas con anormalidades inmunes. | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| JP2016536303A5 (https=) | ||
| BR112015018213A2 (pt) | método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente | |
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
| BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. | |
| JP2017505897A5 (https=) | ||
| Clark et al. | In-sample tests of predictive ability: A new approach | |
| BR112015026685A2 (pt) | agente de diminuição de ácido úrico | |
| WO2015073710A3 (en) | Detection of atherosclerotic cardiovascular disease risk | |
| ES2560577A1 (es) | Sensor electroquímico y procedimiento de recubrimiento, procedimiento de fabricación y usos correspondientes | |
| WO2012074882A3 (en) | Phagocytic activity as a marker of synucleinopathic disease | |
| WO2015069883A3 (en) | Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2015048804A3 (en) | Protein biomarker and uses thereof | |
| EA201500924A1 (ru) | Способ определения модифицирующей активности |